Valuation: ValiRx plc

Market Cap 12.28L 16.53L 14.44L 13.33L 23.15L 16Cr 23.67L 1.59Cr 62.66L 7.79Cr 62.07L 60.71L 27Cr P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 4L 6L 5L 5L 8L 5.68Cr 8L 56.83L 22.35L 2.78Cr 22.14L 21.66L 9.57Cr EV / Sales 2024
2,72,64,249x
EV / Sales 2025 5,41,21,446x
Free-Float
93.4%
Yield 2024 *
-
Yield 2025 -
1 week+10.34%
1 month-13.51%
3 months-44.83%
6 months-58.44%
Current year-52.24%
1 week 0.14
Extreme 0.14
0.18
1 month 0.13
Extreme 0.13
0.19
Current year 0.13
Extreme 0.13
0.48
1 year 0.13
Extreme 0.13
0.85
3 years 0.13
Extreme 0.13
15
5 years 0.13
Extreme 0.13
65
10 years 0.13
Extreme 0.13
1,436.25
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Director/Board Member 62 25/07/2024
Chairman 59 25/07/2024
Date Insider Type Main position Quantity % Market Cap.
04/03/26 Buy

Chief Executive Officer

10,00,000 0.1346%
18/10/22 Free

Director

75,000 0.0832%
18/10/22 Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+10.34%-77.14%-97.59% 16.53L
-7.17%-4.39%+45.51%+79.00% 5.21TCr
+0.24%-1.54%+53.22%+71.85% 5.38TCr
+0.80%-6.31%+3.98%+423.29% 2.35TCr
-0.09%-0.01%-17.62%-14.67% 2.31TCr
-5.95%-2.58%+30.67%-9.58% 1.94TCr
-1.14%+0.03%+31.57%-30.42% 1.76TCr
-5.16%-7.00%+168.44%+306.37% 1.52TCr
-6.91%-5.83%+26.53%+636.97% 1.48TCr
+0.43%-1.03%+24.63%+191.40% 1.41TCr
Average -2.50%-1.33%+28.98%+155.66% 2.34TCr
Weighted average by Cap. -2.80%-2.36%+40.12%+144.10%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.45 0.1 0.65 0.25 3.16 0.25 0.25 10.87 0.03 0.04 0.04 0.03 0.06 4.06 0.06 0.41 0.16 1.99 0.16 0.16 6.85
Net income -19.16L -25.77L -22.52L -20.78L -36.11L -25Cr -36.91L -2.48Cr -97.71L -12Cr -96.79L -94.66L -42Cr -22.32L -30.03L -26.24L -24.22L -42.07L -29Cr -43.01L -2.89Cr -1.14Cr -14Cr -1.13Cr -1.1Cr -49Cr
Net Debt -15.44L -20.77L -18.15L -16.75L -29.1L -20Cr -29.75L -2Cr -78.75L -9.8Cr -78.02L -76.3L -34Cr -8L -10.63L -9L -9L -14.89L -10Cr -15.22L -1.02Cr -40.3L -5.01Cr -39.92L -39.05L -17Cr
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
17/26/17 GBX 0.1600 0.00% 8,36,147
16/26/16 GBX 0.1600 -5.88% 87,02,406
15/26/15 GBX 0.1700 +17.24% 5,24,01,401
14/26/14 GBX 0.1450 0.00% 43,92,285
13/26/13 GBX 0.1450 0.00% 4,750

Annual profits - Rate of surprise